Novartis Acquires Encore Vision

 Novartis Acquires Encore Vision

Novartis recently announced it has entered into a definitive agreement to acquire Encore Vision, Inc. — a privately-held company in Fort Worth, TX focused on the development of a novel treatment in presbyopia.

Encore Vision's lead investigational product is EV06 — reportedly a first-in-class topical treatment for presbyopia. In a phase I/II proof of concept study, 50 patients were reportedly treated daily for 90 days with topical EV06 and 25 patients with a placebo. At day 90, 82 percent of participants treated with EV06 had 20/40 near vision versus 48 percent in the placebo group.

Click here to read the full press release.

Source: Novartis

  • <<
  • >>